Table 1.
Demographic and clinical characteristics of 192 patients with breast cancer treated at a community hospital who were in- (IC) or out-of-criteria (OOC) with NCCN guidelines for germline testing
| IC (N = 104) | OOC (N = 88) | p | |
|---|---|---|---|
| N (%) | N (%) | ||
| Patient sex | 0.061 | ||
| Female | 98 (94.2) | 88 (100.0) | |
| Male | 6 (5.8) | 0 (0.0) | |
| Clinician-reported race/ethnicity | 0.306 | ||
| Asian | 3 (2.9) | 0 (0.0) | |
| Black/African American | 3 (2.9) | 1 (1.1) | |
| Hispanic or Latino—other | 0 (0.0) | 1 (1.1) | |
| Hispanic or Latino—unknown | 1 (1.0) | 0 (0.0) | |
| White | 98 (94.2) | 86 (97.8) | |
| Family history of cancer (breast, ovary, pancreas or prostate) | < 0.001 | ||
| Yes | 85 (81.7) | 46 (52.3) | |
| No | 19 (18.3) | 42 (47.7) | |
| Personal history of nonbreast cancer | 0.791 | ||
| Yes | 8 (7.7) | 5 (5.7) | |
| No | 96 (92.3) | 83 (87.5) | |
| Stage | 0.058 | ||
| 0 | 10 (9.6) | 13 (14.8) | |
| I | 63 (58.7) | 59 (67.0) | |
| II | 14 (13.5) | 8 (9.1) | |
| III | 6 (5.8) | 3 (3.4) | |
| IV | 9 (8.7) | 0 (0) | |
| Unknown | 4 (3.7) | 5 (5.7) | |
| Hormone receptor (HR)/ERBB2 status | 0.504 | ||
| HR+/ERBB2− | 75 (72.1) | 63 (71.6) | |
| HR+/ERBB2+ | 4 (3.8) | 4 (4.5) | |
| HR−/ERBB2+ | 7 (6.7) | 3 (3.4) | |
| HR−/ERBB2− | 9 (8.7) | 4 (4.5) | |
| Unknown | 9 (8.7) | 14 (15.9) |